ELI LILLY & Co is 745.0x more valuable than Palvella Therapeutics, Inc. by market capitalization ($1.072 T vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | PVLA | LLY |
|---|---|---|
| Market cap | $1.44 B | $1.072 T |
| US-listed rank | #2360 | #10 |
| Revenue (latest FY) | $42.81M | $65.18B |
| Net income (latest FY) | -$41.72M | $20.64B |
| Net margin | -97.4% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 774 | 989 |
ELI LILLY & Co is 745.0x more valuable than Palvella Therapeutics, Inc. by market capitalization ($1.072 T vs $1.44 B).
In their latest fiscal years, Palvella Therapeutics, Inc. reported $42.81M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Palvella Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.